High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer.

Braunschweig, I

High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. [electronic resource] - Cytotherapy 2000 - 105-10 p. digital

Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

1465-3249

10.1080/146532400539107 doi


Adult
Aged
Antigens, CD34--metabolism
Blood Component Removal
Blood Transfusion, Autologous--adverse effects
Breast Neoplasms--blood
Female
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation--adverse effects
Humans
Middle Aged
Survival Rate
Time Factors
Treatment Outcome